Recent developments in the management of severe asthma

Area of Science:

• Pulmonology
• Clinical Pharmacology

Background:

• Severe asthma management remains challenging.
• Biomarker-guided therapies are evolving.
• Understanding treatment efficacy in diverse severe asthma phenotypes is crucial.

Purpose of the Study:

• To evaluate the potential of fevipiprant and tezepelumab as future treatments for severe asthma.
• To assess treatment efficacy across different severe asthma patient subgroups.

Main Methods:

• Review of clinical trial data and published literature.
• Analysis of treatment outcomes for fevipiprant and tezepelumab.
• Comparison of efficacy in patients with and without eosinophilic inflammation.

Main Results:

• Fevipiprant demonstrated limited efficacy and is unlikely for severe asthma.
• Tezepelumab showed significant benefits in severe asthma patients.
• Tezepelumab's efficacy was consistent across eosinophilic and non-eosinophilic phenotypes.

Conclusions:

• Fevipiprant is not a viable option for severe asthma.
• Tezepelumab represents a promising new therapeutic avenue for severe asthma.
• Tezepelumab offers a potential treatment for a broad range of severe asthma patients.